What are the fundraising trends in the cell therapy market?

In our cell therapy market deck, you will find everything you need to understand the market

This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market

Is more or less capital going into the cell therapy market?

Less capital went into the cell therapy market in 2025 than in 2024, but the freshest 2026 signal points to a partial rebound rather than continued collapse. Full-year capital fell from about $3.33B in 2024 to about $1.38B in 2025, while year-to-date 2026 capital reached about $974M through the start of May.

The cleanest structural comparison is 2024 versus 2025, because those are both complete years. On that basis, the cell therapy market went through a major funding reset: capital fell by roughly 58%, even though the number of disclosed deals rose from 20 to 28.

The current-year comparison tells a different story. Year-to-date 2026 funding is running well ahead of the comparable 2025 period, with about $974M across 11 deals versus about $370M across 9 deals. That means capital has reopened, but only for a narrow set of companies.

The practical takeaway is that the cell therapy market is not simply down or back. It compressed sharply in 2025, then began 2026 with a selective reopening for companies with late-stage assets, public-market access, or clear clinical and commercial milestones.

Is cell therapy funding driven by more deals or larger rounds?

Cell therapy funding is currently being driven more by larger rounds than by a broad expansion in deal count. The year-to-date 2026 market has only two more deals than the comparable 2025 period, but it has raised about 2.6 times as much capital.

The 2024-to-2025 comparison shows why deal count alone can be misleading. Deal count rose from 20 to 28, but total capital fell from about $3.33B to about $1.38B. More companies found money in 2025, but fewer companies found very large money.

The round-size data makes the signal clearer. Median round size dropped from $137M in 2024 to $34M in 2025, then moved back up to about $60M in year-to-date 2026. Average round size also recovered from about $41M in the comparable 2025 window to about $89M in 2026.

The megaround pattern confirms the same point. In 2024, 19 of 20 deals were above $50M. In 2025, only 10 of 28 deals were above $50M. So far in 2026, 7 of 11 deals are above $50M, which means the market is recovering through selective scale financings, not mass participation.

For deeper benchmarks on round sizes, medians, and deal-size buckets, see the cell therapy market deck.

Is cell therapy capital moving toward later-stage or earlier-stage companies?

Cell therapy capital is moving decisively toward later-stage companies in 2026, even though 2025 briefly showed stronger early-stage formation. In year-to-date 2026, about 94% of capital went to late-stage companies, while only about 6% went to seed and Series A.

The full-year comparison adds important nuance. In 2024, the cell therapy market was already late-stage-heavy, with Series B-plus and growth equity representing about 86% of capital. In 2025, early-stage funding became more visible, with Series A representing about $580M, or roughly 42% of total capital.

That early-stage opening has not carried forward into 2026 so far. Cytotheryx is the only qualifying first financing in the year-to-date dataset, and the rest of the market is dominated by follow-ons, public offerings, growth equity, Series C, and Series D+ rounds.

The practical takeaway is that the cell therapy market is currently rewarding proof over novelty. Investors are not refusing new companies, but the center of gravity has moved toward companies that can show credible clinical, regulatory, manufacturing, or commercialization progress.

This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies

Is the cell therapy market maturing or still experimental?

The cell therapy market is maturing in capital allocation, but it remains experimental at the technology frontier. The funding pattern is no longer dominated by broad scientific exploration; it is increasingly dominated by follow-on rounds, late-stage assets, and companies with milestone proximity.

The clearest 2026 evidence is that 10 of 11 deals are follow-ons and roughly 94% of capital has gone to late-stage companies. That is the behavior of a proof market, not a market where investors are spraying capital across many early hypotheses.

At the same time, the science is still evolving quickly. The funded universe includes allogeneic platforms, iPSC-derived therapies, CAR-T, organ-regenerative cell therapies, stem-cell programs, and late-stage transplant-adjacent products. The modality map is still broad, even if the capital map is narrower.

The honest interpretation is that the cell therapy market is maturing financially before it is finished technologically. Investors are still interested in new approaches, but they are attaching much higher value to evidence, manufacturability, and a credible route to patients.

Are new startups still entering the cell therapy market?

Yes, new startups are still entering the cell therapy market, but new-company formation has weakened sharply in 2026 after being meaningfully stronger in 2025. First financings rose from 15% of deals in 2024 to about 39% in 2025, then fell to only 1 of 11 year-to-date 2026 deals.

The 2025 formation window was real. Dispatch Bio, Stylus Medicine, Azalea Therapeutics, Link Cell Therapies, MagicRNA Biotech, and several smaller Asia-Pacific and European companies showed that investors were still willing to fund new cell therapy platforms.

The 2026 picture is different. Cytotheryx’s $60M Series A is the only qualifying first financing so far, and one company cannot support a broad claim that startup formation remains healthy. The cell therapy market is currently prioritizing existing companies that need capital to reach clinical, regulatory, or commercial milestones.

This does not mean the door is closed to new entrants. It means a new cell therapy company now needs a tightly framed therapeutic thesis, credible translational path, and enough starting capital to survive CMC, manufacturing, clinical, and regulatory complexity.

For more context on first financings and new-company formation, see the full cell therapy market report.

Are more investors entering the cell therapy market?

More investors entered the cell therapy market in 2025, but the year-to-date 2026 evidence points to a narrower and more selective investor base. The strongest full-year signal is that unique disclosed investors rose from at least 55 in 2024 to roughly 80 to 90 in 2025.

That 2025 broadening came with more deals, more first financings, more Asia-Pacific participation, and more European activity. The investor base included specialist biotech funds, strategic pharma investors, public-market participants, regional funds, and family offices.

So far in 2026, the visible investor universe is smaller. The dataset contains about 29 unique disclosed investors and roughly 8 named tier-1 investors, although public offerings obscure buyer identity and make the count incomplete.

The better conclusion is that 2025 broadened the cell therapy investor base, while 2026 has so far narrowed it toward investors and financing structures willing to back clinically validated or late-stage assets. More investors may still appear later in the year, but the current evidence supports selectivity, not broad investor inflow.

This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups

Are top investors getting more or less active in cell therapy?

Top investors are getting less visibly repeat-active in the cell therapy market so far in 2026, even though high-quality investors remain present in individual deals. The clearest signal is that no disclosed investor appears in more than one qualifying year-to-date 2026 deal.

That is different from the prior two years. In 2024, repeat names included The Column Group, Alexandria Venture Investments, RA Capital Management, Cormorant Asset Management, Novo Holdings, and others. In 2025, The Column Group and Alexandria each appeared in three deals, and several other top investors appeared more than once.

The year-to-date comparison is especially important. Over the comparable 2025 period, The Column Group and Cormorant each appeared more than once. So far in 2026, top names such as TCGX, RA Capital, RTW, Venrock, Qiming, and Lightspeed appear, but as isolated deal participants rather than repeat category deployers.

The practical takeaway is that top investors have not abandoned the cell therapy market. They are underwriting asset-by-asset, and one marquee investor on one deal should be read as validation of that company, not proof that the whole category has reopened broadly.

Which cell therapy subcategories are gaining momentum?

Late Stage Cell Therapies and Allogeneic Cell Therapies are gaining the clearest momentum in the cell therapy market so far in 2026. Together, they represent roughly three-quarters of all year-to-date capital.

Late Stage Cell Therapies are the most obvious capital winner. Only two deals, MEDIPOST and Orca Bio, captured about $390M, or roughly 40% of year-to-date 2026 capital. Their capital-share-to-deal-share ratio is 2.20, which means investors are paying a clear premium for late-stage proof.

Allogeneic Cell Therapies combine breadth and capital depth. Century Therapeutics, Ernexa Therapeutics, and Allogene Therapeutics together produced three deals and about $346M. That suggests investors are still willing to fund off-the-shelf and iPSC-derived models when the company has enough clinical or public-market relevance.

Regenerative Cell Therapies are gaining momentum in a more mixed way. They have three deals, tied for the highest category count, but only about $116M of capital. The category is active, but it has not yet matched the capital intensity of late-stage or allogeneic programs.

We cover this category rotation in more detail in the deeper analysis of the cell therapy market.

Which cell therapy subcategories are losing momentum?

CAR T Therapies, Engineered Immune Cells outside mainstream CAR-T, and Autologous Cell Therapies are losing relative momentum in the cell therapy market, though for different reasons. CAR-T is losing capital share rather than strategic relevance, while the other two categories show weaker current visibility.

The clearest relative decline is CAR-T. CAR T Therapies captured about 54% of capital in 2024 and 53% in 2025, but only about 12% of year-to-date 2026 capital. That is a major shift in the funding center of gravity.

That does not mean CAR-T is obsolete. OriCell and Lyell still show that CAR-T remains strategically relevant. The point is narrower: investors are no longer treating CAR-T as the whole cell therapy market.

Autologous Cell Therapies are the weakest current category by capital. They account for only one small $2M year-to-date 2026 deal, or about 0.2% of capital. The likely issue is not scientific value; it is that investors increasingly penalize patient-specific manufacturing complexity unless the company has unusually strong clinical or commercial proof.

This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy

Which regions are gaining momentum in cell therapy funding?

Asia-Pacific is gaining the most relative momentum in cell therapy funding, while North America remains the dominant region by capital and deal count. In year-to-date 2026, Asia-Pacific captured about $261M, or roughly 27% of capital, from 3 of 11 deals.

The improvement is meaningful because Asia-Pacific had no qualifying deals in the 2024 dataset and then reached 9 deals and about $183M in full-year 2025. So far in 2026, it has already surpassed its full-year 2025 capital total with fewer deals.

The most important detail is that the 2026 Asia-Pacific rounds are not tiny. MEDIPOST raised $140M, OriCell raised $70M, and Regend raised about $51M. Asia-Pacific’s average deal size is now close to North America’s average deal size in the current-year sample.

North America is still gaining in absolute dollar terms versus early 2025, but Asia-Pacific is gaining share. That means the cell therapy market remains North America-led, but it is no longer exclusively North America-driven.

Which regions are losing momentum in cell therapy funding?

Europe is losing momentum most clearly in the cell therapy market, at least in the qualifying disclosed equity financings captured through the start of May 2026. Europe had about $633M in 2024, about $98M in 2025, and no qualifying year-to-date 2026 deals.

The full-year comparison shows that Europe’s decline was already visible before 2026. In 2024, Europe represented 19% of capital, largely because Autolus raised a large financing package. In 2025, Europe represented 21% of deals but only 7% of capital.

That means European cell therapy activity broadened by deal count in 2025 but compressed in round size. Europe had companies raising money, but not at the same scale as North America.

The current-year signal should be read carefully because 2026 is incomplete. Still, zero qualifying European deals through the start of May is too stark to ignore. The cell therapy market’s current financing map is North America plus Asia-Pacific, with Europe temporarily missing.

Is cell therapy becoming more global or more regionally concentrated?

The cell therapy market is becoming more global than it was in 2024, but capital remains regionally concentrated in North America and a small number of Asia-Pacific rounds. The company map is wider than before, but the dollar map is still narrow.

The full-year comparison shows globalization in deal count. In 2024, North America captured 90% of deals, Europe captured the rest, and Asia-Pacific had no qualifying deals. In 2025, North America’s deal share fell to 46%, while Asia-Pacific rose to 32% and Europe reached 21%.

Capital did not globalize as much as deal count. In 2025, North America still captured about 80% of dollars despite representing less than half of deals. Asia-Pacific captured 13% and Europe captured 7%.

In year-to-date 2026, the market is a two-region story: North America has about 73% of capital and Asia-Pacific has about 27%. The real signal is globalization at the frontier, not full geographic democratization.

For ongoing regional tracking across North America, Asia-Pacific, Europe, and other regions, see the market report covering cell therapy geography.

This chart, featured in our cell therapy market deck, shows how CAR-T approvals have driven growth in the cell therapy market over time

Is cell therapy capital moving toward proven winners or new opportunities?

Cell therapy capital is currently moving toward proven winners, after a 2025 period that briefly funded more new opportunities. So far in 2026, 10 of 11 deals are follow-ons, about 94% of capital has gone to late-stage companies, and first financings account for only about 6% of capital.

The 2025 counterpoint matters. First financings represented about 39% of deals and 37% of capital, while Series A financings represented about 42% of total dollars. That was a genuine new-opportunity year by cell therapy standards.

But 2026 has moved back toward proven-winner financing. Orca Bio, Allogene, MEDIPOST, Century, OriCell, Regend, and Lyell all fit a follow-on validation pattern more than an open-ended startup formation pattern.

The concentration metrics reinforce the point. The top three year-to-date 2026 deals account for about 61% of capital, and the top five account for about 82%. That means the cell therapy market is backing a limited number of companies investors believe can reach meaningful milestones.

Is the cell therapy market becoming winner-takes-most?

Yes, the cell therapy market is becoming winner-takes-most in capital allocation, even though the pattern is not a single-company monopoly. In year-to-date 2026, the top three deals account for about 61% of capital, and the top five account for about 82%.

That is much more concentrated than either complete prior year. In 2025, the top three deals captured about 32% of capital and the top five captured about 47%. In 2024, the top three captured about 36% and the top five captured about 49%.

The bottom-half share tells the same story from the other side. The bottom half of year-to-date 2026 deals captured only about 18% of capital. Smaller public placements and bridge-like financings may add to deal count, but they do not define the capital pool.

The caveat is that 2026 is incomplete. With only 11 deals, concentration can be distorted by a few large January and April financings. Still, the current pattern is strong enough to treat as a real signal: credibility gradients are steepening.

Is the next wave of cell therapy winners becoming visible?

The next wave of cell therapy winners is becoming visible, but it looks more like a short list of validated scale-up companies than a broad cohort of new startups. In 2026, the most visible names are Orca Bio, Allogene, MEDIPOST, Century, OriCell, Regend, Lyell, and Cytotheryx.

That list is important because it cuts across different versions of cell therapy. It includes late-stage transplant-adjacent programs, allogeneic platforms, CAR-T, regenerative therapies, and organ-focused cell therapy approaches. The next wave is not one modality.

What these companies have in common is not youth. Most are follow-on stories with clinical, regulatory, public-market, or commercialization relevance. Cytotheryx is the exception as a first financing, but even that round is a substantial $60M Series A around a defined regenerative liver therapy thesis.

The practical filter is simple. The next winners in the cell therapy market are likely to be companies that can turn platform complexity into milestone clarity. Investors are not just funding the idea of cell therapy; they are funding companies that can show how the product gets manufactured, tested, regulated, and eventually delivered to patients.

For more detail on repeat raisers, large financings, and the companies defining the current cycle, see the full market view on cell therapy winners.

As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily

Is the cell therapy funding landscape fragmenting or consolidating?

The cell therapy funding landscape is consolidating at the top of the capital stack while remaining fragmented across modalities. Investors are still funding multiple cell therapy categories, but the largest checks are clustering around a narrower group of late-stage or clinically validated companies.

The fragmentation is visible in the category map. Year-to-date 2026 funding spans Late Stage Cell Therapies, Allogeneic Cell Therapies, CAR T Therapies, Regenerative Cell Therapies, and Autologous Cell Therapies. That breadth matters because the market is no longer simply a CAR-T funding category.

The consolidation is visible in the capital distribution. The top three year-to-date 2026 deals captured about 61% of capital, and the top five captured about 82%. That means most dollars are not spreading evenly across the category map.

The right way to describe the current state is asymmetric. The cell therapy market is fragmenting technologically, but consolidating financially around companies with proof, scale, and milestone proximity.

Where is investor attention shifting in cell therapy?

Investor attention in the cell therapy market is shifting toward late-stage proof, allogeneic models, and Asia-Pacific scale. It is also shifting away from broad early experimentation and toward companies that can connect science to a clear value-creating milestone.

The late-stage signal is the most important. Orca Bio, MEDIPOST, Allogene, Century, OriCell, Regend, and Lyell are not primarily discovery-stage bets. They are companies with clinical, public-market, regulatory, or commercialization-linked narratives.

The allogeneic signal also matters. Allogeneic Cell Therapies have three deals and about $346M in year-to-date 2026 capital, showing that off-the-shelf and iPSC-derived models remain investable when the proof bar is high enough.

Finally, the regional signal is changing. Asia-Pacific has become a meaningful current-year capital contributor, not just a source of smaller local financings. MEDIPOST, OriCell, and Regend show that Asia-Pacific cell therapy rounds can now reach the same general scale as North American rounds in the qualifying dataset.

For real-time tracking of category rotation, regional momentum, and investor focus, see the cell therapy market report.

This chart, featured in our cell therapy market deck, shows how CAR-T cell therapy technology has evolved over time

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.